Gregory Madden

Managing Partner - SV Health Investors

📍 Boston, Massachusetts, United States🔄 Updated October 2026💼 4 investments📅 10 years investing🗓 Last invested Mar 2024
Angel investor🌍 United States
4
Total investments
0
Early stage
0
Mid stage
2
Late stage
10y
Years active

Portfolio

3 investments · sorted by recency
All investments
Early stage
Mid stage
Late stage
Investor
Mar 2024
Miach Orthopaedics is transforming anterior cruciate ligament tear treatment with the BEAR® Implant
Board Observer
Sep 2016
Baxter is committed to helping you save and sustain lives. Our diagnostic cardiology products support you in gaining accurate information about abnormal rhythm events to help you diagnose and treat patients with confidence. From resting electrocardiogram (ECG) to diagnostic stress testing to continuous ambulatory cardiac monitoring, we are innovating to provide you diagnostic accuracy and cost-effective solutions that help deliver care without compromise.
Board Observer
Jul 2016
Endotronix, a digital health medtech company, is developing an integrated platform to provide comprehensive, reimbursable health management tools for patients suffering from advanced heart failure. The Cordella™ Heart Failure System includes a cloud-based disease-management system and a breakthrough implantable wireless pulmonary artery pressure sensor. The seamlessly integrated system enables proactive management and early detection of worsening heart failure, which promotes ongoing therapeutic interventions to improve quality of life, reduce hospital readmissions, and lower care costs.
Experience · 5 entries
All (5)
Investments (4)
Board (3)
2024
Investor
Mar 2024
Miach Orthopaedics is transforming anterior cruciate ligament tear treatment with the BEAR® Implant
2020
Managing Partner
Dec 2020
SV Health Investors is a specialist healthcare fund manager, investing across stages, geographic regions, and sectors, with expertise spanning biotechnology, dementia, healthcare growth, healthcare technology. Alongside our core funds, SV manages the Dementia Discovery Fund, focused on discovering and developing novel therapeutics for dementia.
2017
Board Observer
Jun 2017
Leiters, founded in 1926, is a trusted FDA-registered 503B outsourcing provider of high-quality hospital and ophthalmology compounded sterile preparations. Leiters is committed to providing healthcare professionals and their patients with high quality outsourced medications. Our team of experts in sterile pharmaceutical manufacturing, repackaging and compounding provide a sophisticated understanding of what it takes to elevate quality and consistency of supply in pharmaceutical outsourcing. The combination of a highly experienced team, with robust processes in a new state-of-the-art outsourcing facility, helps to ensure delivery of the highest quality medicines. All sterile preparations are produced under the Human Drug Outsourcing Facilities under 503B of the FD&C Act (503B Guidance) and follow Current Good Manufacturing Practices (cGMP). To learn more about how we're Compounding Health™ please visit www.leiters.com
2016
Board Observer
Sep 2016
Baxter is committed to helping you save and sustain lives. Our diagnostic cardiology products support you in gaining accurate information about abnormal rhythm events to help you diagnose and treat patients with confidence. From resting electrocardiogram (ECG) to diagnostic stress testing to continuous ambulatory cardiac monitoring, we are innovating to provide you diagnostic accuracy and cost-effective solutions that help deliver care without compromise.
Board Observer
Jul 2016
Endotronix, a digital health medtech company, is developing an integrated platform to provide comprehensive, reimbursable health management tools for patients suffering from advanced heart failure. The Cordella™ Heart Failure System includes a cloud-based disease-management system and a breakthrough implantable wireless pulmonary artery pressure sensor. The seamlessly integrated system enables proactive management and early detection of worsening heart failure, which promotes ongoing therapeutic interventions to improve quality of life, reduce hospital readmissions, and lower care costs.
Investment activity
2016–2024 · 4 investments
201622017120241
Recent (last 2 years)Earlier